NDA 200677 · Recordati Rare
Signifor
Pasireotide Diaspartate · Subcutaneous · Somatostatin Analog
NovelOrphanLast checked: Nov 19, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 14, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
1,194
962 serious, 108 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 17, 2026.
SIGNIFOR is a somatostatin analog indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative ( 1 ) 1.1 Cushing's Disease SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
Mechanism: SIGNIFOR is an injectable cyclohexapeptide somatostatin analogue. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTRs). Five human somatostatin receptor subtypes are known: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Corticotroph tumor cells from Cushing's disease patients frequently over-express SSTR5 whereas the other receptor subtypes are often not expressed or are expressed at lower levels. Pasireotide binds and activates the SSTRs resulting in inhibition of ACTH...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 15, 2020 Supplement 6 · Efficacy LabelLetter
- Dec 14, 2012 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewLetter
3 products under this application
- SIGNIFOR · PASIREOTIDE DIASPARTATE EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- SIGNIFOR · PASIREOTIDE DIASPARTATE EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- SIGNIFOR · PASIREOTIDE DIASPARTATE EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pasireotide Diaspartate" as an intervention, any sponsor and status, largest first.
- Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaActive, not recruiting
RECORDATI GROUPIndustry
NCT05928390 · 93 participants · Start Jan 4, 2024 · Primary completion Oct 29, 2026
Drug: Pasireotide Diaspartate · For: Post-Bariatric Hypoglycemia
Sites: Palo Alto, California; Chicago, Illinois; Metairie, Louisiana · 29 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea163
- hyperglycaemia144
- diabetes mellitus136
- fatigue125
- drug ineffective122
- blood glucose increased121
- diarrhoea121
- off label use114
- headache88
- vomiting83
- dizziness74
- hypoglycaemia62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 43 |
| 2014 | 94 |
| 2015 | 120 |
| 2016 | 116 |
| 2017 | 106 |
| 2018 | 73 |
| 2019 | 86 |
| 2020 | 116 |
| 2021 | 71 |
| 2022 | 86 |
| 2023 | 86 |
| 2024 | 67 |
| 2025 | 77 |
| 2026 | 51 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Signifor (Pasireotide Diaspartate)
2024 spending
$2.1M
Beneficiaries
19
107 claims
Per beneficiary
$110,547
$327.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $789,420 |
| 2023 | $1,492,015 |
| 2024 | $2,100,391 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease Patients.
Nedelman J, Fisch R, Hu K, et al. · Clin Pharmacokinet 2018 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Recordati Rare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.